Roche (OTC: RHHBY) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IgG Antibody to herpes simplex virus (HSV) types 1 and 2 assays for use on cobas® modular platforms. The tests are intended for use with sexually active individuals and expectant mothers as an aid in the presumptive diagnosis of HSV-1 and HSV-2 infection.
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
0 comments
- Get Livefyre
- FAQ
Newest | Oldest
